MA33034B1 - Gène codant pour un mutant de glucokinase humaine, enzyme codée par celui-ci, vecteurs recombinants et hôtes recombinants, compositions pharmaceutiques et leurs utilisations, procédés de traitement et de prévention de maladies - Google Patents

Gène codant pour un mutant de glucokinase humaine, enzyme codée par celui-ci, vecteurs recombinants et hôtes recombinants, compositions pharmaceutiques et leurs utilisations, procédés de traitement et de prévention de maladies

Info

Publication number
MA33034B1
MA33034B1 MA34075A MA34075A MA33034B1 MA 33034 B1 MA33034 B1 MA 33034B1 MA 34075 A MA34075 A MA 34075A MA 34075 A MA34075 A MA 34075A MA 33034 B1 MA33034 B1 MA 33034B1
Authority
MA
Morocco
Prior art keywords
gene
human
preventing
pharmaceutical compositions
treatment
Prior art date
Application number
MA34075A
Other languages
Arabic (ar)
English (en)
Inventor
Haidong Huang
Original Assignee
Haidong Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haidong Huang filed Critical Haidong Huang
Publication of MA33034B1 publication Critical patent/MA33034B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'INVENTION PORTE SUR UN GÈNE CODANT POUR UN MUTANT DE GLUCOKINASE HUMAINE. LE GÈNE A LA SÉQUENCE NUCLÉOTIDIQUE CHOISIE PARMI LA SÉQUENCE NUCLÉOTIDIQUE ÉNUMÉRÉE COMME ÉTANT SEQ ID NO:2 ET LA SÉQUENCE NUCLÉOTIDIQUE DANS LAQUELLE LA RÉGION DE CADRE DE LECTURE OUVERT (ORF) CODE POUR LA MÊME SÉQUENCE D'ACIDES AMINÉS QUE CELLE CODÉE PAR LA RÉGION ORF (POSITION 487 À 1 884) DE SEQ ID NO:2 ET LA RÉGION RESTANTE EST IDENTIQUE À LA RÉGION NON-ORF DE SEQ ID NO:2. L'INVENTION PORTE ÉGALEMENT SUR UN MUTANT DE GLUCOKINASE HUMAINE CODÉ PAR LE GÈNE, SUR LES VECTEURS RECOMBINANTS PORTANT LE GÈNE, SUR LES HÔTES COMPRENANT LES VECTEURS, SUR DES COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI, SUR LEURS UTILISATIONS ET SUR DES PROCÉDÉS DE TRAITEMENT ET DE PRÉVENTION DE MALADIES À L'AIDE DE CEUX-CI. LE MUTANT DE GLUCOKINASE HUMAIN CODÉ PAR LE GÈNE A UNE ACTIVITÉ SUPÉRIEURE À CELLE DE LA GLUCOKINASE HUMAINE DE TYPE SAUVAGE, ET AINSI FOURNIT UNE NOUVELLE FAÇON DE RÉGULER LE GLUCOSE SANGUIN OU DE PRÉVENIR ET DE TRAITER UNE PERTURBATION DU MÉTABOLISME GLUCIDIQUE, NOTAMMENT DE PRÉVENIR ET DE TRAITER LE DIABÈTE.
MA34075A 2009-01-07 2010-01-06 Gène codant pour un mutant de glucokinase humaine, enzyme codée par celui-ci, vecteurs recombinants et hôtes recombinants, compositions pharmaceutiques et leurs utilisations, procédés de traitement et de prévention de maladies MA33034B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910000087 2009-01-07
PCT/CN2010/070038 WO2010078842A1 (fr) 2009-01-07 2010-01-06 Gène codant pour un mutant de glucokinase humaine, enzyme codée par celui-ci, vecteurs recombinants et hôtes recombinants, compositions pharmaceutiques et leurs utilisations, procédés de traitement et de prévention de maladies

Publications (1)

Publication Number Publication Date
MA33034B1 true MA33034B1 (fr) 2012-02-01

Family

ID=42316263

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34075A MA33034B1 (fr) 2009-01-07 2010-01-06 Gène codant pour un mutant de glucokinase humaine, enzyme codée par celui-ci, vecteurs recombinants et hôtes recombinants, compositions pharmaceutiques et leurs utilisations, procédés de traitement et de prévention de maladies

Country Status (21)

Country Link
US (1) US9029142B2 (fr)
EP (1) EP2388317B1 (fr)
JP (1) JP5721637B2 (fr)
KR (1) KR101300540B1 (fr)
CN (1) CN102272296B (fr)
AP (1) AP3277A (fr)
AU (1) AU2010204379B2 (fr)
BR (1) BRPI1006104B8 (fr)
CA (1) CA2749180C (fr)
DK (1) DK2388317T3 (fr)
EA (1) EA024878B1 (fr)
ES (1) ES2649021T3 (fr)
HU (1) HUE035110T2 (fr)
IL (1) IL213750A (fr)
MA (1) MA33034B1 (fr)
MX (1) MX2011007263A (fr)
NZ (1) NZ593893A (fr)
PT (1) PT2388317T (fr)
SG (1) SG172851A1 (fr)
WO (1) WO2010078842A1 (fr)
ZA (1) ZA201105209B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009334452B2 (en) 2008-12-29 2015-06-11 Tel Hashomer Medical Research, Infrastructure And Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
AU2010204379B2 (en) 2009-01-07 2014-02-13 Yiyuan (Shenzhen) Biotech Limited Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
WO2013117776A1 (fr) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Enzymes glucokinases à activité accrue, et leur utilisation pour le traitement et/ou la prévention du diabète sucré
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2016069475A1 (fr) 2014-10-27 2016-05-06 Aseko, Inc. Gestion sous-cutanée de patient externe
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
CN110564777B (zh) * 2019-09-23 2021-09-10 北京希诺谷生物科技有限公司 糖尿病疾病模型犬的建立方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297375A1 (fr) * 1997-07-24 1999-02-04 Valentis, Inc. Systeme d'expression de ghrh et procedes d'utilisation
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ES2170720B1 (es) * 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US20070219346A1 (en) * 2002-04-22 2007-09-20 Mcgill University Glucose sensor and uses thereof
WO2005052132A2 (fr) * 2003-11-24 2005-06-09 Exelixis, Inc Utilisation de modulateurs de la morphogenese de ramification comme genes modificateurs de la morphogenese de ramification et leurs procedes d'utilisation
GB0423173D0 (en) * 2004-10-19 2004-11-24 Univ Newcastle Treatment of diabetes
CN101212977A (zh) * 2005-06-01 2008-07-02 国际创新生物技术研究所有限公司 葡萄糖可诱导的胰岛素表达和治疗糖尿病的方法
DK2185696T3 (en) * 2007-08-10 2015-10-26 Univ Sydney Tech Cells genetically modified to include pancreatic glucokinase, and uses thereof
AU2010204379B2 (en) 2009-01-07 2014-02-13 Yiyuan (Shenzhen) Biotech Limited Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases

Also Published As

Publication number Publication date
KR20110099057A (ko) 2011-09-05
BRPI1006104A2 (pt) 2016-02-16
AU2010204379A1 (en) 2011-07-28
CA2749180C (fr) 2017-03-21
MX2011007263A (es) 2011-10-06
IL213750A0 (en) 2011-07-31
EP2388317A1 (fr) 2011-11-23
JP2012514463A (ja) 2012-06-28
PT2388317T (pt) 2017-11-27
CA2749180A1 (fr) 2010-07-15
ZA201105209B (en) 2012-09-26
US20110286984A1 (en) 2011-11-24
BRPI1006104B8 (pt) 2021-05-25
KR101300540B1 (ko) 2013-09-02
AU2010204379B2 (en) 2014-02-13
HUE035110T2 (en) 2018-05-02
EA201170917A1 (ru) 2011-12-30
CN102272296A (zh) 2011-12-07
SG172851A1 (en) 2011-08-29
EA024878B1 (ru) 2016-10-31
AP2011005814A0 (en) 2011-08-31
EP2388317B1 (fr) 2017-08-30
AP3277A (en) 2015-05-31
IL213750A (en) 2015-11-30
EP2388317A4 (fr) 2012-11-28
JP5721637B2 (ja) 2015-05-20
DK2388317T3 (da) 2017-11-27
BRPI1006104B1 (pt) 2021-04-20
ES2649021T3 (es) 2018-01-09
CN102272296B (zh) 2012-10-24
NZ593893A (en) 2013-02-22
US9029142B2 (en) 2015-05-12
WO2010078842A1 (fr) 2010-07-15

Similar Documents

Publication Publication Date Title
MA33034B1 (fr) Gène codant pour un mutant de glucokinase humaine, enzyme codée par celui-ci, vecteurs recombinants et hôtes recombinants, compositions pharmaceutiques et leurs utilisations, procédés de traitement et de prévention de maladies
Du et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells
Hudey et al. Mechanisms of non-type 2 asthma
Miglio et al. PPARγ stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss
Toborek et al. HIV‐Tat protein induces oxidative and inflammatory pathways in brain endothelium
Warner-Schmidt et al. A role for p11 in the antidepressant action of brain-derived neurotrophic factor
Dmytriyeva et al. The metastasis-promoting S100A4 protein confers neuroprotection in brain injury
Zeng et al. The glucagon like peptide 1 analogue, exendin-4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression
Zhang et al. Cerebral mast cells participate in postoperative cognitive dysfunction by promoting astrocyte activation
Jarry et al. Secreted osteoclastogenic factor of activated T cells (SOFAT), a novel osteoclast activator, in chronic periodontitis
Laukens et al. Human metallothionein expression under normal and pathological conditions: mechanisms of gene regulation based on in silico promoter analysis
Hong et al. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast
AU2020202676A1 (en) Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5
WO2014121083A1 (fr) Procédé d'augmentation de la connectivité neuronale et/ou de traitement d'une condition neurodégénérative
US20240024304A1 (en) Methods of managing conditioned fear with neurokinin receptor antagonists
US20210162029A1 (en) Compositions and methods for treatment or prevention of skin diseases and disorders with lekti
KR20160037169A (ko) 레트 증후군 및 그를 위한 치료
Russell et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms
Chen et al. Therapeutic efficacy of cyclosporin A against spinal cord injury in rats with hyperglycemia
Stefanovic et al. Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives
KR20160070154A (ko) 미토콘드리아병을 치료하기 위한 시스테아민 및 이의 유도체의 용도
Ganguly et al. Triplication of HSA21 on alterations in structure and function of mitochondria
RU2001130755A (ru) Диагностика риска развития у субъекта атеросклероза или диабетической ретинопатии
Testa et al. Cholinergic striatal neurons are increased in HSAN V homozygous mice despite reduced NGF bioavailability
KR102127218B1 (ko) 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도